Tratamiento farmacológico en tiempos de incertidumbreuso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19

  1. Mayayo Vicente, S. 1
  2. F. Rodriguez Salvanés 1
  3. A. Gallego-Arenas 1
  4. L.M. Sánchez-Gómez 1
  5. M. Ruiz-López 1
  6. B. Sierra García 1
  7. A. Jurado-López 2
  8. Arriola Bolado, Paloma 2
  9. M. Cervera Cano 2
  10. B. Novella-Arribas 1
  1. 1 Instituto de Investigación Hospital Universitario de La Princesa. ISCIII, Madrid, España
  2. 2 Unidad de Evaluación de Tecnologías Sanitarias, Dirección General de Planes Integrados de Salud, Consejería de Sanidad, Comunidad de Madrid, Madrid, España
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2020

Issue Title: COVID19 en Atención Primaria

Issue: 1

Pages: 20-27

Type: Article

DOI: 10.1016/J.SEMERG.2020.06.016 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

Background and objectives : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID-19 disease, a systematic review of published studies and RCT studies publishes until April 28, 2020 was carried out. Material and methods A systematic search was carried out in PubMed with the keywords COVID-19 and their synonyms and hydroxychloroquine/chloroquine. The data selection and extraction was elaborated by two researchers, independently. The results were discussed with a Primary Care physicians clinical group and the results were synthesized using GRADE methodology. Results A good quality systematic review was found that includes articles with a high risk of bias. And 8 EC launched that will produce results beyond May 2020. Conclusions Although the conclusions of the systematic review generate a low confidence in the results, and the clinical variables that show benefit are intermediate variables, the side effects are acceptable and could be minimized with the use of QT lengthening risk tools, so it is could make a weak recommendation in favor of the use of chloroquine/hydroxychloroquine in patients with mild-moderate stage COVID-19.

Bibliographic References

  • X. Yao, F. Ye, C. Cui, B. Huang, P. Niy, X. Liu, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Cli Infect Dis. (2020), 10.1093/cid/ciaa237 Google Scholar
  • J. Liu, R. Cao, M. Xu, X. Wang, H. Zhang, H. Hu, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Cell Discov., 6 (2020), p. 16, 10.1038/s41421-020-0156-0 CrossRefView Record in ScopusGoogle Scholar
  • A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, S. Einav A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 J Crit Care., 57 (2020), pp. 279-32830397, 10.1016/j.jcrc.2020.03.005 View Record in ScopusGoogle Scholar
  • S. Shah, S. Das, A. Jain, D.P. Misra, V.S. Negi A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19) Int J Rheum Dis., 23 (2020), pp. 613-619, 10.1111/1756-185X.13842 CrossRefView Record in ScopusGoogle Scholar
  • S. Sarma, H. Kaur, H. Kumar, D. Mahendru, P. Avti, A. Bhattacharyya, et al. Virological and clinical cure in covid-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis J Med Virol., 92 (2020), pp. 776-785, 10.1002/jmv.25898 CrossRefView Record in ScopusGoogle Scholar
  • Chen Z, Hu J, Zhang Z, Jiang S, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv Prepr Serv Health Sci. 2020. https://doi.org/10.1101/2020.03.22.20040758. Google Scholar
  • J. Chen, D. Liu, P. Liu, Q. Xu, L. Xia, Y. Ling, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ Med Sci., 49 (2020), pp. 215-219 View Record in ScopusGoogle Scholar
  • P. Gautret, J.C. Lagier, P. Parola, V.T. Hiang, L. Meddeb, M. Mailhe, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Int J Antimicrob Agents. (2020), 10.1016/j.ijantimicag.2020.105949 Google Scholar
  • J.M. Molina, C. Delaugerre, J.L. Golf, B. Mela-Lina, D. Ponscarme, L. Goldwirt, N. De Castro No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Med Mal Infect., 50 (2020), p. 384, 10.1016/j.medmal.2020.03.006 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Million, J.-C. Lagier, P. Gautret, P. Colson, P.-E. Fournier, S. Amrane Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille France Mediterr-Infect. (2020) https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract_Raoult_EarlyTrtCovid19_09042020_vD1v.pdf Google Scholar
  • P. Gautret, J.-C. Lagier, P. Parola, V.T. Hoang, L. Meddeb, J. Sevestre Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study Mediterr-Infect. (2020) https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf Google Scholar
  • E. Chorin, D. Matthew, E. Shulman, L. Wadhwani, R. Kohen, C. Barbhiya, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin medRxiv. (2020), 10.1101/2020.04.02.20047050 Google Scholar
  • AIHTA Policy Letter No.: 002; 2020 Viena: HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Google Scholar
  • European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes [consultado Abr 2020]. Disponible en: https://www.ema.europa.eu/en/news/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes Google Scholar
  • Medicines and Healthcare products Regulatory Agency. Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment [consultado Abr 2020]. Disponible en: https://www.gov.uk/government/news/chloroquine-and-hydroxychloroquine-not-licensed-for-coronavirus-covid-19-treatment Google Scholar
  • FDA. Emergency Use Authorization [consultado Abr 2020]. Disponible en: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covidtherapeutics Google Scholar
  • J.L. Goodman, L. Borio Finding effective treatments for COVID-19: Scientific integrity and public confidence in a time of crisis JAMA., 323 (2020), pp. 1899-1900, 10.1001/jama.2020.6434 CrossRefView Record in ScopusGoogle Scholar
  • B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19 N Engl J Med., 382 (2020), pp. 1787-1799, 10.1056/NEJMoa2001282 CrossRefView Record in ScopusGoogle Scholar
  • J. Barbosa, D. Kaitis, R. Freedman, K. Le, X. Lin Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: A quasi-randomized comparative study N Engl J Med. (2020) (manuscript on review) Google Scholar
  • Agencia Española de Medicamentos y Productos Sanitarios. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2. Fecha de publicación: 28 de Abr de 2020. Ministerio de Sanidad. España. Google Scholar
  • J.E. Tisdale, H.A. Jaynes, J.R. Kingery, N.A. Mourad, T.N. Trujillo, B.R. Overhomser, R. Kovacs Development and validation of a risk score to predict QT interval prolongation in hospitalized patients Circ Cardiovasc Qual Outcomes., 6 (2013), pp. 479-487 View Record in ScopusGoogle Scholar
  • T.F. Simpson, R.J. Kovacs, E.C. Stecker Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19 Cardiology Magazine. (2020) https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 Google Scholar
  • D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, W.S. Richardson Evidence based medicine: what it is and what it isn’t BMJ., 312 (1996), pp. 71-72 CrossRefView Record in ScopusGoogle Scholar
Data source: Dialnet